Taliglucerase alfa
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](https://docslib.b-cdn.net/cover/8870/ehealth-dsi-ehdsi-v2-2-2-or-ehealth-dsi-master-value-set-1028870.webp)
Top View
- Clinical Policy: Taliglucerase Alfa (Elelyso)
- Cerezyme® (Imiglucerase), Elelyso® (Taliglucerase Alfa) and VPRIV® (Velaglucerase Alfa) Effective: April 13, 2021
- ELELYSO Powder for Injection Is Packaged in a 13.5 Ml Type 1 Borosilicate Glass Vial
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Enzyme Replacement Therapy for Lysosomal Diseases: Lessons from 20 Years of Experience and Remaining Challenges
- 2; Potential Implications for the Pathogenesis of Gaucher and Parkinson's Diseases
- Lysosomal Storage Diseases and Glycan Degradation
- Introduction to FDA Review and Approval of Biological Products
- 5.01.576 Drugs for Rare Diseases
- Alphabetical Listing by Therapeutic Category Dod UNIFORM
- ELELYSO (Taliglucerase Alfa) RATIONALE for INCLUSION IN
- Elelyso, INN-Taliglucerase Alfa
- Product Monograph
- Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective
- Lysosomal Storage Disease Overview
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Past Vs. Present New Generation of Specialty Management